{"id":139,"date":"2026-01-30T10:32:10","date_gmt":"2026-01-30T09:32:10","guid":{"rendered":"https:\/\/serenada-alzheimer.info\/?page_id=139"},"modified":"2026-02-09T14:33:44","modified_gmt":"2026-02-09T13:33:44","slug":"polityka-dostepu-rozszerzonego","status":"publish","type":"page","link":"https:\/\/serenada-alzheimer.info\/pl\/expanded-access-policy\/","title":{"rendered":"Polityka dost\u0119pu rozszerzonego"},"content":{"rendered":"<div class=\"wp-block-group style-legal has-accent-1-color has-text-color has-link-color has-medium-font-size wp-elements-1 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading\">Polityka dost\u0119pu rozszerzonego<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Firma Exciva opracowuje obecnie produkt badawczy (EXV-802) przeznaczony do potencjalnego leczenia pobudzenia u os\u00f3b z chorob\u0105 Alzheimera. Exciva rozumie, \u017ce mog\u0105 istnie\u0107 osoby zainteresowane uzyskaniem dost\u0119pu do leku EXV-802 poza badaniem klinicznym. Na tym etapie rozwoju jedynym sposobem uzyskania dost\u0119pu do EXV-802 jest udzia\u0142 w badaniu klinicznym.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Exciva jest w pe\u0142ni zaanga\u017cowana we wspieranie os\u00f3b cierpi\u0105cych na chorob\u0119 Alzheimera, u kt\u00f3rych wyst\u0119puj\u0105 stany pobudzenia, oraz ich rodzin, d\u0105\u017c\u0105c do uzyskania zatwierdzenia regulacyjnego, aby zapewni\u0107 dost\u0119p jak najwi\u0119kszej liczbie os\u00f3b, kt\u00f3re mog\u0105 odnie\u015b\u0107 z tego najwi\u0119ksze korzy\u015bci. Poniewa\u017c Exciva gromadzi wi\u0119cej danych klinicznych dotycz\u0105cych bezpiecze\u0144stwa i skuteczno\u015bci leku EXV-802, firma w razie potrzeby dok\u0142adnie rozwa\u017cy polityk\u0119 rozszerzonego dost\u0119pu, aby upewni\u0107 si\u0119, \u017ce jest ona zgodna z najlepszymi interesami takich os\u00f3b.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">W razie jakichkolwiek pyta\u0144 dotycz\u0105cych polityki dost\u0119pu rozszerzonego firmy Exciva, prosimy o kontakt&nbsp;<a href=\"mailto:studies@exciva.com\">studies@exciva.com<\/a>. Prosimy nie przesy\u0142a\u0107 nam \u017cadnych osobistych informacji dotycz\u0105cych zdrowia.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Expanded access policy Exciva is currently developing an investigational product (EXV-802) for potential treatment for agitation in people with Alzheimer\u2019s Disease. Exciva understands that there may be people who are interested in access to EXV-802 outside of a clinical trial. At this stage of development, the only way to gain access to EXV-802 is by [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-139","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/pages\/139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/comments?post=139"}],"version-history":[{"count":6,"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/pages\/139\/revisions"}],"predecessor-version":[{"id":291,"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/pages\/139\/revisions\/291"}],"wp:attachment":[{"href":"https:\/\/serenada-alzheimer.info\/pl\/wp-json\/wp\/v2\/media?parent=139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}